EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC: COMPARISON OF VALUE TO PRICE

被引：0
|
作者：
Doyle, J. J. [1 ]
Wood, B. [1 ]
机构：
[1] IQVIA, New York, NY USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.536
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCP61
引用
收藏
页码：S91 / S91
页数：1
相关论文
共 50 条
  • [41] Inside PD-1/PD-L1,2 with their inhibitors
    Boisgerault, Nicolas
    Bertrand, Philippe
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 256
  • [42] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [43] Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
    Suszczyk, Dorota
    Skiba, Wiktoria
    Zardzewialy, Witold
    Pawlowska, Anna
    Wlodarczyk, Karolina
    Polak, Grzegorz
    Tarkowski, Rafal
    Wertel, Iwona
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [44] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
  • [45] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
    Jiang, Siqing
    Li, Xin
    Huang, Lihua
    Xu, Zhensheng
    Lin, Jinguan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [46] VALUE ASSESSMENT OF PROPORTIONAL HAZARDS TESTINGS IN ONCOLOGY HTA SUBMISSIONS FOR PD-1/PD-L1 INHIBITORS - A NICE PERSPECTIVE
    Sharma, S.
    Singh, B.
    Mangat, G.
    Siddiqui, M. K.
    VALUE IN HEALTH, 2020, 23 : S70 - S70
  • [47] The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
    Chen, Li
    Zhao, Ruihu
    Sun, Hao
    Huang, Rong
    Pan, Hongming
    Zuo, Yanjiao
    Zhang, Lele
    Xue, Yingwei
    Li, Xingrui
    Song, Hongjiang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [48] The expression level and prognostic value of PD-L1 and PD-1 in cervical carcinoma patients.
    Zhang, Songan
    Bao, Yong Xing
    Huerxidan, Niyazi
    Liu, Pan
    Zhao, Huarong
    Gulixian, Tuluwengjiang
    Zhang, Yang
    Xiao, Lei
    Su, Weipeng
    Dilidaer, Sidike
    Ye, Jianwei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
    Jelinek, T.
    Hajek, R.
    ONCOIMMUNOLOGY, 2016, 5 (12):
  • [50] Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?
    Saleh, Khalil
    Khalifeh-Saleh, Nadine
    Kourie, Hampig Raphael
    IMMUNOTHERAPY, 2018, 10 (05) : 345 - 347
12345